Key result
Higher NT-proBNP cut-offs in HF trials increase event rates ~19% but worsen screening failures.
Why the study?
NT-proBNP is widely used as an enrichment criterion in heart failure RCTs, but cut-offs vary and evidence-based guidance is needed to optimize the balance between event enrichment and screening failure across subgroups.
Does applying higher NT-proBNP inclusion cut-offs optimize event enrichment versus screening failure in heart failure trials?
Does applying higher NT-proBNP inclusion cut-offs optimize event enrichment versus screening failure in heart failure trials?
Higher NT-proBNP inclusion cut-offs in HF trials successfully enrich for clinical events but increase screening failures, suggesting cut-offs should be tailored to specific trial aims and patient subgroups like obesity and CKD.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Supports tailored NT-proBNP cut-offs by HF trial aim and subgroup; extends evidence on enrichment versus screening failure trade-offs.
Aims N-terminal pro–B-type natriuretic peptide (NT-proBNP) is widely used as an enrichment criterion in heart failure (HF) randomized controlled trials (RCTs), yet cut-offs vary. This study aims to provide evidence-based guidance on selecting NT-proBNP cut-offs to optimize the balance between event enrichment and screening failure across HF subgroups. Methods Using the Swedish HF Registry (SwedeHF), we applied NT-proBNP cut-offs from prior RCTs (200–5000 pg/mL) and calculated 1-year incidence proportions of a composite CV outcome (CV death or first HF hospitalisation) across subgroups by ejection fraction (EF), care setting (inpatient/outpatient), atrial fibrillation (AF), chronic kidney disease (CKD), and obesity. We quantified point and relative increases in event proportions and potential screening failure at each cut-off and identified optimal prognostic thresholds by maximizing Youden’s index. Results Among 43,750 HF patients, median NT-proBNP was lower in HFpEF/HFmrEF vs HFrEF, outpatients vs inpatients, sinus rhythm vs AF, obese vs not obese, and patients without CKD vs with CKD (all p < 0.001). Higher NT-proBNP cut-offs increased 1-year composite CV proportions but excluded more patients. For example, In HFrEF outpatients, the 1-year proportion rose from 22.0% (no cut-off) to 24.3% at ≥600 pg/mL and 26.2% at ≥1,200 pg/mL, a 19% (95% CI:14.0–24.4) relative increase. Screening failure rose from 16.0% to 26.4% at these respective cut-offs. Optimal prognostic thresholds aligned with or exceeded subgroup median NT-proBNP values. Conclusion Higher NT-proBNP cut-offs were associated with increased event enrichment but also higher screening failure. These findings support the use of higher cut-offs currently used in HF RCTs and suggest that future trials should tailor NT-proBNP cut-offs to trial aims, balancing enrichment with enrolment feasibility and considering obesity and CKD in addition to EF and AF.
Schroeder et al. (2026) studied this question. Higher NT-proBNP cut-offs in heart failure trials increase event enrichment, with a ≥1,200 pg/mL threshold yielding a 19% relative increase in 1-year events but raising screening failure to 26.4%.
Synapse has enriched 10 related papers. Consider them for comparative context: